CMMB — Chemomab Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $4.29m
- -$5.07m
Annual cashflow statement for Chemomab Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -5.95 | -12.5 | -27.6 | -24.2 | -13.9 |
| Depreciation | |||||
| Non-Cash Items | 0.324 | 2.23 | 4.12 | 0.754 | 0.668 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.361 | -2.16 | 3.1 | -0.211 | -2.16 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -5.24 | -12.4 | -20.4 | -23.6 | -15.4 |
| Capital Expenditures | -0.038 | -0.239 | -0.068 | -0.003 | 0 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.024 | -44.9 | 19.6 | 15.9 | 2.3 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.062 | -45.2 | 19.5 | 15.9 | 2.3 |
| Financing Cash Flow Items | 1.25 | 2.43 | -1.22 | 0 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 4.75 | 61.1 | -0.808 | 3.5 | 9.87 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.554 | 3.51 | -1.65 | -4.23 | -3.22 |